multitargeted antifolate ly231514 (Eli Lilly)
90
Structured Review
Eli Lilly
multitargeted antifolate ly231514
Multitargeted Antifolate Ly231514, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitargeted+antifolate+ly231514/pemetrexed+alimta+ly231514/10__1021_slash_acs__orglett__0c01227-124-12-15
Average 90 stars, based on 1 article reviews
Multitargeted Antifolate Ly231514, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/multitargeted+antifolate+ly231514/pemetrexed+alimta+ly231514/10__1021_slash_acs__orglett__0c01227-124-12-15
Average 90 stars, based on 1 article reviews
multitargeted antifolate ly231514 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Designing Homogeneous Copper-Free Sonogashira Reaction through a Prism of Pd–Pd Transmetalation Article Snippet: As a part of our anticancer investigations, we have been interested in Article Title: Phase I and Pharmacologic Study of Sequences of Gemcitabine and the Multitargeted Antifolate Agent in Patients With Advanced Solid Tumors Article Snippet: Purpose: Multitargeted antifolate (MTA) is an investigational agent that, like gemcitabine, exhibits broad activity in solid tumors.. A phase I trial of MTA and gemcitabine was undertaken, based on the demonstration of preclinical cytotoxic synergy.. Patients and Methods: Thirty-five patients (group I) received 164 courses (median, four; range, one to 14 courses) of treatment of gemcitabine at doses of 1,000 and 1,250 mg/m2 on days 1 and 8 and MTA at doses of 200, 300, 400, 500, and 600 mg/m2, given 90 minutes after gemcitabine on day 1. Article Title: Designing Homogeneous Copper-Free Sonogashira Reaction through a Prism of Pd–Pd Transmetalation Article Snippet: As a part of our anticancer investigations,29 we have been interested in |